公开(公告)号：US20230330240A1

公开(公告)日：2023-10-19

申请号：US17912563

申请日：2021-03-25

Applicant: Biohaven Therapeutics Ltd.

Inventor： Alexander Sergei BAYDEN ,  Tetyana BERBASOVA ,  Lawrence Emerson FISHER ,  Wieslaw KAZMIERSKI ,  Luca RASTELLI ,  Tomi K. SAWYER ,  David Adam SPIEGEL ,  Wayne Charles WIDDISON

IPC: A61K47/68 ,  A61P31/14 ,  A61K47/18 ,  A61K47/08

CPC classification number: A61K47/6801 ,  A61K47/08 ,  A61K47/18 ,  A61P31/14

Abstract: Among other things, the present disclosure provides agents that can bind to viruses such as SARS-CoV-2 and/or cells infected thereby. In some embodiments, the present disclosure provides methods for preventing and/or treating conditions, disorders or diseases associated with SARS-CoV-2 infection. In some embodiments, the present disclosure provides methods for preventing and/ or treating COVID-19.

公开(公告)号：US20230190719A1

公开(公告)日：2023-06-22

申请号：US17923585

申请日：2021-06-23

Applicant: Biohaven Therapeutics Ltd.

Inventor： Robert BERMAN ,  Rajesh KUMAR ,  Charles M. CONWAY ,  Mary K. DONOHUE ,  Ajaya Kumar REKA

IPC: A61K31/4402 ,  A61K9/00 ,  A61K45/06 ,  A61K47/44

CPC classification number: A61K31/4402 ,  A61K9/0014 ,  A61K45/06 ,  A61K47/44

Abstract: Provided is a pharmaceutical formulation including (1S)-1-phenyl-2-pyridin-2-ylethanamine, a pharmaceutically acceptable salt thereof, a solvate thereof, or a prodrug thereof; and a pharmaceutically acceptable topical carrier. Also provided is a method for treating neuropathic pain by administering to a patient in need of such treatment a therapeutically effective amount of the pharmaceutical formulation.

公开(公告)号：US20230181541A1

公开(公告)日：2023-06-15

申请号：US17923587

申请日：2021-06-24

Applicant: Biohaven Therapeutics Ltd.

Inventor： Vladimir CORIC ,  Robert BERMAN ,  Loren AGUIAR

IPC: A61K31/428 ,  A61P25/18

CPC classification number: A61K31/428 ,  A61P25/18

Abstract: Disclosed herein is a method for treating obsessive-compulsive disorder in a patient in need thereof by administering to the patient a dosage form including an effective amount of troriluzole.

公开(公告)号：US11083711B2

公开(公告)日：2021-08-10

申请号：US16544166

申请日：2019-08-19

Applicant: BIOHAVEN THERAPEUTICS LTD.

Inventor： Anthony Marfat

IPC: C07D277/82 ,  A61K31/428 ,  A61K9/14 ,  C07D417/12 ,  C07F9/6541 ,  A61K47/16

Abstract: Disclose are amine prodrugs and methods of synthesis thereof. In particular, the amine prodrug comprises a drug molecule and at least one or more prodrug appendage moieties and the method for synthesis the amine prodrug comprises a step of coupling the drug molecule and at least one or more prodrug appendage moieties. Also disclosed are exemplary riluzole prodrugs and methods of synthesis thereof.

公开(公告)号：US20210236471A1

公开(公告)日：2021-08-05

申请号：US17164654

申请日：2021-02-01

Applicant: Biohaven Therapeutics Ltd.

Inventor： Jay Edward Wrobel ,  Allen B. Reitz ,  Jeffrey Claude Pelletier ,  Garry Robert Smith ,  Haiyan Bian

IPC: A61K31/428 ,  A61P25/00 ,  A61P25/28 ,  A61K38/06 ,  C07K5/083 ,  C07K5/087 ,  C07D277/82 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K38/05 ,  A61K45/06 ,  C07D417/12 ,  C07K5/062 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20

Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

公开(公告)号：US20210236470A1

公开(公告)日：2021-08-05

申请号：US17151582

申请日：2021-01-18

Applicant: Biohaven Therapeutics Ltd.

Inventor： Jay Edward Wrobel ,  Allen B. Reitz ,  Jeffrey Claude Pelletier ,  Garry Robert Smith ,  Haiyan Bian

IPC: A61K31/428 ,  A61P25/00 ,  A61P25/28 ,  A61K38/06 ,  C07K5/083 ,  C07K5/087 ,  C07D277/82 ,  A61K31/454 ,  A61K31/496 ,  A61K31/5377 ,  A61K38/05 ,  A61K45/06 ,  C07D417/12 ,  C07K5/062 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20

Abstract: Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

公开(公告)号：US20250066351A1

公开(公告)日：2025-02-27

申请号：US18726772

申请日：2023-01-06

Applicant: Biohaven Therapeutics Ltd.

Inventor： Lynn RESNICK ,  Justin K. BELARDI ,  Charles A. FLENTGE ,  David A. MARESKA ,  George T. TOPALOV ,  Steven A. BOYD ,  James S. HALE

IPC: C07D471/04 ,  A61K31/437 ,  A61K31/444

Abstract: Compounds such as those represented by Formula I can be potent for the Kv7.2/7.3 heteromultimer. These compounds may be used to treat a number of medical conditions, and may be included in dosage forms, pharmaceutical compositions, or medicaments.

公开(公告)号：US20240252674A1

公开(公告)日：2024-08-01

申请号：US18555857

申请日：2022-05-17

Applicant: Biohaven Therapeutics Ltd.

Inventor： Wieslaw KAZMIERSKI ,  Gene M. DUBOWCHIK ,  Reese M. CALDWELL ,  David Adam SPIEGEL

IPC: A61K47/68 ,  A61K47/64

CPC classification number: A61K47/6889 ,  A61K47/64 ,  A61K47/6835

Abstract: Among other things, the present disclosure provides technologies for site-directed conjugation of various moieties of interest to target agents. In some embodiments, the present disclosure utilizes target binding moieties to provide high conjugation efficiency and selectivity. In some embodiments, provided technologies are useful for preparing antibody conjugates.

公开(公告)号：US20240238436A1

公开(公告)日：2024-07-18

申请号：US18555855

申请日：2022-05-17

Applicant: BIOHAVEN THERAPEUTICS LTD.

Inventor： Wieslaw KAZMIERSKI ,  Richard PRACITTO

IPC: A61K47/68 ,  A61K45/06 ,  A61K47/64 ,  C07K7/06 ,  C07K16/18

CPC classification number: A61K47/6811 ,  A61K45/06 ,  A61K47/64 ,  A61K47/6843 ,  A61K47/6889 ,  C07K7/06 ,  C07K16/18

Abstract: A composition including a first compound having the structure P-N-LPM-MOI, wherein P-N is a protein agent moiety comprising a lysine residue, LPM is a linker, and MOI is a moiety of interest, and a second compound having the structure LG-OH, wherein LG is a group comprising a target binding moiety that binds to a target agent.

公开(公告)号：US11834418B2

公开(公告)日：2023-12-05

申请号：US17127231

申请日：2020-12-18

Applicant: BIOHAVEN THERAPEUTICS LTD.

Inventor： Lynn Resnick ,  George T. Topalov ,  Justin K. Belardi ,  James S. Hale ,  Scott S. Harried ,  Charles A. Flentge ,  David A. Mareska

IPC: C07D235/30 ,  C07D413/04 ,  C07D401/04 ,  C07D405/12 ,  C07D403/04 ,  C07D401/12

CPC classification number: C07D235/30 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D405/12 ,  C07D413/04

Abstract: Optionally substituted benzoimidazol-1,2-yl amides, such as compounds of Formula 1 or Formula 2, can be used to treat disorders associated with a Kv7 potassium channel activator. Compositions, medicaments, and dosage forms related to the treatment are also disclosed herein.